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Background: The IgG1 and IgG3 antibodies are considered cytophilic and protective against
Plasmodium falciparum, whereas IgG2 and IgG4 are thought to block protective mechanisms.
Objectives: The main objective was to measure antibodies directed against erythrocyte binding
antigen-175 (EBA-175) peptide 4 and analyze the relationship between such antibodies and clinical
malaria attack.
Methods: Using an enzyme-linked immunosorbent assay, a retrospective analysis of naturally acquired
antibodies to synthetic peptide from EBA-175 peptide 4 has been carried out in 158 school children
from the village of Dienga in Gabon.
Results: The overall prevalence rates of antibodies to EBA-175 peptide 4 were 85.2%, 66.8%, 52.6%,
71.6% and 64.0% for total IgG, IgG1, IgG2, IgG3 and IgG4, respectively. Protection from clinical malaria,
determined after a prospective 1-year study, was associated with the levels of IgG and IgG1 antibodies
that increased with age.
Conclusion: Together, these data suggest that age/exposure-related acquisition of anti-EBA-175
antibodies may contribute to the development of clinically protective immunity and could be taken
into account in malaria control strategies when they are confirmed.
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1
Currently efforts are focused on the development of a
vaccine against the human malaria parasite, Plasmodium
falciparum, as an alternative to drug therapy or vector control. 
P. falciparum uses a 175 kDa sialic acid binding protein ligand
known as erythrocyte binding antigen-175 (EBA-175) for
erythrocyte invasion.1-4 The gene encoding EBA-175 has been
sequenced from both the FCR3 and CAMP strains of 
P. falciparum.5-7 While it is now well established that EBA-175 is 
a dimorphic antigen, the role that dimorphism plays in 
host-parasite interactions (including putative differences in red
blood cell invasion efficiency) remains unclear. However, the
initial molecular interaction between the parasite and the
erythrocyte involves binding of a conserved domain (region II) of
EBA-175 to sialic acid residues from glycophorin A followed by
proteolytic cleavage of EBA-175 and binding of the dimorphic F
and C segments to the glycophorin A back bone.7 A conserved
region of 42 amino acids (aa) of EBA-175, termed EBA-peptide
4 (1062-1103) within region V, has been implicated in the binding
to erythrocytes,8 although it is not essential for the initial sialic
acid-dependent binding.4
EBA-175 is considered a potential vaccine candidate because
it induces antibodies that inhibit malaria merozoite invasion.9
The recombinant fragments of EBA-175 are recognized by
human sera from malaria endemic areas.10 Antibodies raised
in mice against EBA-peptide 4 blocked binding of native
EBA-175 to human erythrocytes and inhibited merozoite
invasion in vitro.8,9 Importantly, an alternative invasion
pathway by P. falciparum merozoites commonly occurs in the
field parasites11 and can also be induced in vitro by targeted
disruption of the EBA-175 gene.12 EBA-175 has a universal
role in merozoite invasion since the antibodies against region
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II block invasion pathways that do not involve sialic acid.13 It
has been demonstrated that EBA-175 is also expressed on
pre-erythrocytic parasites14 and that immunization with
EBA-region II protects Aotus monkeys from P. falciparum
challenge.15 Although EBA-175 antigen is likely to be
involved in the development of protective immunity against
malaria, the antibody response to EBA-175 in humans living
in malaria endemic regions remains poorly characterized,16
including the response to EBA-peptide 4 which is predicted
to include a B-cell epitope.6
The aim of the present study was to measure antibodies
directed against EBA peptide 4, as well as isotype
distribution in school children living in Dienga, Gabon. The
influence of age on the levels of these antibodies has been
investigated, as well as their relationship with parasite density
and occurrence of clinical malaria attack during a 12-month
follow-up.
Materials and Methods
Subjects and field methods
The village under study was Dienga in southeast Gabon
where a clinical, biological and parasitological follow-up
was carried out among the primary school-going population
during the whole malaria transmission season of 1995.17
Clinical and parasitological data allowed us to distinguish
between protected and unprotected children. Briefly,
protected children were defined as those who never
presented during the whole survey with a febrile episode
(defined as axillary temperature >37˚C) associated with
neither P. falciparum parasitemia >400/µl nor the presence
of 4-aminoquinoline metabolite in urine. Unprotected
children were defined as those who presented with at least
one malaria attack defined as the association of fever and
parasitemia ≥5000/µl.17,18 The unique criterion of selection
was the availability of sufficient quantity of plasma, which
was obtained for 158 children.
Moreover, from February 1995 to March 1996, all children
were routinely screened for P. falciparum infection by finger
prick blood sampling every 2 weeks and also whenever fever
occurred. The thick blood smears were prepared and stained
with Giemsa. Parasite densities were recorded as the number
of parasites/µl of blood, assuming an average leukocyte count
of 8000/µl. Each value of parasite density was simultaneously
adjusted to age and date of sampling by calculating the ratio of
individual parasite density (parasite density + 1) to the
geometric mean of all (parasite density + 1) values recorded at
each date of sampling in the group of children of the same age.
For each child who presented at least six recorded thick blood
smears, the geometric mean of date and age adjusted (GMA)
parasite densities was calculated. For the need of statistical
analysis, log-transformed values of the GMA parasite density
were considered.
Antigen and antibody measurements
A synthetic peptide used as antigen was EBA-peptide 
4 (aa 1062-1103:SNNEYKVNEREDERTLTKEYEDIVLKS
HMNRESDDGELYDEN). This peptide was synthesized by
Interactiva Biotechnology (Ulm, Germany). The plasma was
collected from 158 children at the end of the follow-up.
Antibodies were measured by enzyme-linked immunosorbent
assay (ELISA) using 1 µg/ml of EBA peptide 4, a 100-fold
diluted plasma and a 2,000-fold diluted goat anti-human IgG
(Fc specific) conjugated to alkaline phosphatase (Sigma, St.
Louis, MO, USA). Bound enzyme was detected with 
p-nitrophenylphosphate and the absorbance was read at 405 nm.
IgG subclass analysis was carried out using 50-fold diluted
plasma, mouse anti-human IgG1, IgG2, IgG3 and IgG4
antibodies (codes: LMH 1013, 1022, 1032 and 1042; Caltag
Laboratories, Burlingame, CA, USA) at a final concentration of
1, 0.25, 0.5, 0.25 µg/ml, respectively, and a goat anti-mouse IgG
at respective final concentrations of 2.5, 5, 1.3 and 2.5 µg/ml.
Bound enzyme was detected as described above. Reference
positive and negative control plasmas were included in each plate
and results were expressed in arbitrary units (AU) calculated as
previously described.19,20 The thresholds for positivity were set
at 45.2 AU for anti-EBA-peptide 4 IgG and 35.6, 93.3, 31.7 and
23.3 AU for IgG1, IgG2, IgG3 and IgG4 isotypes, respectively,
as determined from the mean reactivity plus 2 SD of 20 plasmas
from non-immune subjects.
Statistical analysis
Differences in proportions were analyzed using the χ2 test.
Differences in means were tested by Student’s unpaired t test
on linear or log-transformed values. When variable
distribution was not normalized by log transformation, the
non-parametric Mann-Whitney U test was employed.
Figure 1. Proportions of individuals with plasma IgG and 
IgG subclass antibodies against EBA-175 peptide 4, as tested
by ELISA. 
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Associations between quantitative variables were assessed by
the Spearman’s rank test of correlation. A logistic regression
using the maximum likelihood ratio method (LR procedure
of BMDP) was used to adjust antibody responses
simultaneously on age and protection status. For all tests, 
P values <0.05 were considered significant.
Results
Recognition of EBA-175 peptide 4 by human antibodies
Clinical, parasitological and hematological results have been
previously reported.17,18 Sex, presence of the sickle cell trait
and P. falciparum parasite density at time of blood draw were
equally distributed among children who had clinical malaria
(unprotected) and those who never experienced a malaria
attack (protected) during the 12-month follow-up. The
overall prevalence rates were 85.5%, 66.8%, 52.6%, 71.6%
and 64.0%, respectively for total IgG, IgG1, IgG2, IgG3 and
IgG4 (figure 1). Both IgG1 and IgG3 antibody prevalence
rates and levels were higher in IgG positive samples (χ2 test
and Mann-Whitney U test, P = 0.0001 in both tests for IgG1,
and P = 0.009 and P = 0.0004, respectively for IgG3). The
levels of IgG4 antibodies were higher in IgG1 and IgG2
responders compared to non-responders (Mann-Whitney 
U test, P = 0.006, P <0.0001, respectively) and were
correlated to the levels of each of the other IgG subclasses
(Spearman: rho = 0.326, P = <0.0001 for IgG1; rho = 0.322,
P = <0.0001 for IgG2; and rho = 0.126, P = <0.07 for IgG3).
The prevalence rate and the levels of IgG1 antibodies were
both higher in IgG2 responders than in non-responders 
(χ2 test, P = 0.03; Spearman: rho = 0.183, P = 0.009).
Influence of age on EBA-175 antibody response
The prevalence rate (Mann-Whitney U test, P = 0.006) and
the level (Spearman: rho = 0.238, P = 0.0006) of IgG1
antibodies to EBA-peptide 4 increased with age (figure 2A).
Total IgG level also increased with age (Spearman: rho =
0.212, P = 0.002) (figure 2B). While anti-EBA-175 IgG2,
IgG3 and IgG4 antibodies did not vary with age, the ratios of
IgG1:IgG2, IgG1:IgG3, and IgG1:IgG4 antibodies increased
with age (Spearman: rho = 0.252, P = 0.0006; rho = 0.153, 
P = 0.05; and rho = 0.276, P = 0.0003, respectively).
Relationships between parasite density and anti-EBA-175
antibody response
Individuals with IgG antibodies to EBA-175 exhibited higher
GMA parasite density than those without IgG (Mann-Whitney
U test, P = 0.04). GMA parasite density also correlated to
IgG1 levels (Spearman: rho = 0.126, P = 0.08).
Association of EBA-175-specific antibodies and resistance to
clinical malaria
Children were monitored for malaria infection and clinical
disease during a prospective 1-year study. EBA-175-specific
antibodies titers were compared between unprotected (who
presented with a clinical malaria attack) and protected
individuals (who did not). The prevalence rate of total IgG was
similar in both groups, but their level was higher in protected
individuals (Mann-Whitney U test, P = 0.0089) (figure 3A).
Furthermore, the prevalence rate (χ2 test, P = 0.02) and the
level (Mann-Whitney U test, P = 0.0428) of IgG1 antibody
were higher in protected than in unprotected children (figure
3B). The logistic regression demonstrated that both age 
(P = 0.049) and IgG1 antibodies (P = 0.045, OR = 2.4, 95%
CI: 1.1-5.5) were independent predictors of protection status.
Moreover, the ratio of cytophilic antibodies IgG1:IgG3 was
also increased in protected as compared to unprotected
children (Mann-Whitney U test, P = 0.02). The prevalence
rates and levels of IgG2, IgG3 and IgG4 antibodies were
similar in both groups of children (figure 3C, 3D and 3E).
Discussion
The immunological effector mechanisms responsible for
protection against malaria are poorly understood and may vary
according to transmission dynamics21,22 and age of exposure
to malaria parasites.23 The development of anti-disease
immunity in children repeatedly infected with P. falciparum is
thought to be related to the rise of immune responses to certain
parasite antigens. In areas of stable transmission, antibodies
recognizing monomorphic epitopes,21.22 polymorphic
epitopes24 and variant epitopes on proteins showing clonal
antigenic variation25-27 have all been suggested to contribute
to this protection. In this study, the anti-EBA-175 peptide 4
IgG isotypes were analyzed in children who either presented
with or not with a malaria attack during a prospective 1-year
follow-up study. To overcome the confounding effects of
antigen polymorphism, we deliberately focused on a
conserved sequence, commonly expressed by P. falciparum.
Our study demonstrated that IgG1, IgG2, IgG3 and IgG4
antibodies from most of the children recognized EBA-175
peptide 4. This clearly indicates that IgG antibodies compete
for binding to EBA-175 epitopes and is consistent with the
role of an isotype imbalance in the resistance and/or
susceptibility to malaria infection.28 A similar subclass
distribution has been reported in studies using EBA-175
Figure 2. Distribution of IgG (A) and IgG1 (B) levels in children
<10 years old and those who are 10 years and older. IgG and
IgG1 levels differed between both groups of children 
(Mann-Whitney U test, P = 0.0020 and 0.0006, respectively).
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recombinant antigens,29 merozoite surface protein 1
(MSP1)30 and MSP2.31,32 Interestingly, our study showed that
protection against clinical malaria was associated with the
presence and levels of IgG1 antibodies to EBA-175 peptide 4
(figure 3B), as well as with the levels of total IgG (figure 3A).
Furthermore, the levels of total IgG and IgG1 antibodies
increased with age (figure 2). Overall, there were no
significant differences in the distribution of IgG2, IgG3 and
IgG4 levels between those who were protected or not against
malaria (figure 3C, 3D and 3E). Although a possible change
in EBA-175 antibody levels through the period of follow-up is
not taken into account, these results are in agreement with
previous findings concerning the antibody response of
naturally infected individuals to P. falciparum antigens. It has
been shown, in a large population study in Gambia, that
antibodies to EBA-175 were predominantly of the IgG1 and
IgG3 subclasses and increased with age. Although the
presence of such antibody was not associated with clinical
protection against malaria, there was a trend indicating that
individuals with high anti-EBA-175 region II IgG levels
presented with some protection.29 Jakobsen et al.33 reported
contrasting observations in antibody response to EBA  peptide
(aa 1076 to 1096) among individuals living in different
endemic regions. Indeed, sera from donors living in Indonesia,
Nigeria and Sudan with long exposure to malaria, had low or
negligible IgG reactivity to EBA  peptide (aa 1076 to 1096).
By contrast, Tanzanian children with clinical malaria had
higher IgG reactivity to this peptide compared to those with
asymptomatic infections. The fact that EBA peptide 
(aa 1076 to 1096) is composed of 20 amino acids within the
EBA-peptide 4 (42 aa) lacking therefore an epitope, may
explain the difference in antibody response directed against this
peptide and EBA-peptide 4.
In our study, anti-EBA-175 IgG and IgG1 were associated
with protection against clinical malaria, but other subclasses
were not. We suggest that this protection of Gabonese
children with high IgG levels was mainly related to the IgG1
subclass, as demonstrated by its higher prevalence rate and
levels among IgG responders. Nevertheless, the cytophilic
antibodies IgG1 and IgG3 act in cooperation with cells in
parasite-killing effector responses, such as opsonization and
antibody-dependent cellular inhibition and, therefore, both
are believed to be involved in protection against 
P. falciparum.34 Since IgG3 antibody seems to be more
efficient than IgG1 in cooperating with accessory cells35,36
and in activating the complement pathway,37 it might be
surprising that anti-EBA-175 specific IgG3 does not appear to
be associated with protection. One likely explanation is that
IgG4 and IgG3 recognize similar epitopes from EBA-175
peptide 4 and that IgG4 competes with IgG3 for binding.
Similar isotypic analysis has been performed in various
endemic areas, but did not reveal a clear pattern of
relationships between isotype distribution and parasite
density or malaria attack incidence. This may be due to
parasite and host genetic factors, to immunoassay used or to
the design of the field study.38 The epidemiological studies
in Papua New Guinea indicated that IgG antibodies to MSP2
were associated with a reduced risk of fever associated with
malaria infection and with a reduced risk of malaria-related
anemia,39,40 but did not characterize the protective subclass.
Conversely, a study in Senegal indicated that an increase in
anti-malarial IgG3 with age was associated with a decreased
risk of clinical malaria, but the specificity of the antibodies
was not investigated.41 Our study showed an association
between parasite density and anti-EBA-175 IgG and IgG1
antibodies. Indeed, the GMA parasite density was higher in
IgG positive than in negative individuals, as well as in
individuals with high levels of IgG1 antibodies. Such
association probably results from a higher parasite density
more efficiently triggering the immune system to produce
EBA-175 antibodies. We determined the subclass of EBA-175
specific IgG in plasma from individuals immunized by
natural exposure to malaria. The most important question
regarding the potential of EBA-175 as a vaccine antigen is
Figure 3. Distribution of plasma antibodies levels (in arbitrary units, AU) to EBA-175 peptide 4 in children who had clinical malaria
(unprotected = NP) and those who had an asymptomatic infection (protected = P). (A) total IgG, (B) IgG1, (C) IgG2, (D) IgG3, (E)
IgG4. The 10th, 25th, 75th and 90th percentile boxes for the AU values of each IgG subclass are presented and the horizontal line within
these percentile boxes indicate the median AU. There were significant differences in the distributions of total IgG and IgG1 levels
between both groups of children (Mann-Whitney U test, P = 0.009 and 0.043, respectively).
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whether EBA-175-specific immune responses are
significantly involved in protective immunity to malaria. Our
data showed that EBA-175 is naturally antigenic, that IgG1
antibodies to EBA-175 peptide 4 are associated with
protection against clinical malaria and further investigation
of relationships between EBA-175 antibodies and malaria
attack incidence is justified.
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